A Phase I Dose Escalation Study of Cisplatin, Pemetrexed and Radiotherapy for Inoperable Stage III Non-Small Cell Lung Cancer.

• Register: Netherlands Trial Register
• Last refreshed on: 28 April 2013
• Main ID: NTR752
• Date of registration: 15/08/2006
• Primary sponsor: Erasmus Medical Center, Department of Pulmonary Medicine
• Public title: A Phase I Dose Escalation Study of Cisplatin, Pemetrexed and Radiotherapy for Inoperable Stage III Non-Small Cell Lung Cancer.
• Scientific title: A Phase I Dose Escalation Study of Cisplatin, Pemetrexed and Radiotherapy for Inoperable Stage III Non-Small Cell Lung Cancer. - A Phase I Dose Escalation Study of Cisplatin, Pemetrexed and Radiotherapy for Inoperable Stage III Non-Small Cell Lung Cancer
• Date of first enrolment: 1/3/2006
• Target sample size: 39
• Recruitment status: recruiting
• URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=752
• Study type: intervention
• Study design: Randomised: No; Masking: None; Control: Not applicable; Group: Crossover; Type: -

Countries of recruitment

The Netherlands

Contacts

• Name: R.J. Klaveren, van

• Name: V.F.M. Surmont

Key inclusion & exclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed diagnosis (bronchial brushings and washings or CT-guided fine needle aspiration) of NSCLC, stage III which is not amenable to surgical resection

2. Unidimensional or bidimensional disease on CT scan of the chest. Measurable tumour and/or nodal mass not exceeding 6 cm in largest diameter.

3. Received no prior chemotherapy or radiation therapy.

4. Performance Status 0-1 on the WHO Scale (Appendix A)

5. Estimated life expectancy of at least 24 weeks.

6. Patient compliance and geographic proximity that allow adequate follow-up.

7. Adequate bone marrow reserve: White blood count (WBC) ³ 3.0 ´ 109/L, platelets ³ 100 ´ 109/L, haemoglobin ³ 6 mmol/L (³ 9.6g/dl )

8. Adequate respiratory function: Forced expiratory volume in 1 second (FEV1) ³1.0 L/s (>30%) and transfer factor for carbon monoxide (DLCO) ³ 40% of predicted.

9. Age ³18 years.

10. Written informed consent from patients.

11. Effective use of contraception for both males and females if appropriate during and for 3 months following end of study.


Exclusion criteria: 1. Evidence of active infection at the discretion of the investigator.

2. Inadequate liver function: bilirubin >1.5 times normal, ALT or AST >3 times normal.

3. Inadequate renal function: calculated creatinine clearance using Cockcroft-Gault formula of < 60 ml/min.

4. Hypercalcemia

5. Evidence of extrathoracic metastases/ Stage IIIB with supraclavicular lymph nodes.

6. Uncontrolled superior vena cava syndrome, haemoptysis causing a decrease of blood hemoglobin of ³1 g/L (³0.062 mmol/L) in 24 hours, or other situations which make complete staging or treatment planning impossible.

7. Pleural effusion with positive cytology.

8. Pregnancy.

9. Breast feeding.

10. Serious concomitant systemic disorder incompatible with the study.

11. Second primary malignancy (except in situ carcinoma of the cervix or adequately treated non-melanomatous skin cancer ), unless off treatment and in remission for greater than 5 years.

12. Use of any investigational agent in the month before enrollment into the study.

13. Any co-morbid pulmonary disease that may put the patient at risk of toxicity: specifically interstitial lung disease (fibrosis) and serious chronic pulmonary disease.

14. Patients who are unable to interrupt aspirin, other nonsteroidal anti-inflammatory drugs for a 5-day period starting 2 days before administration of pemetrexed (8-day period for long acting agents such as piroxicam). Patients that cannot be treated with folic acid and vitamin B12 and dexamethasone.

15. Presence of clinically detectable (by physical examination) third-space fluid collections, for example ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to the study entry.

16. Use of Growth factors



Age minimum:
Age maximum:
Gender:

Health Condition(s) or Problem(s) studied

Lung cancer

Intervention(s)

All patients will receive one cycle of pemetrexed 500 mg/m2 and cisplatin 80 mg/m2 (standard systemic dose) before concurrent radiotherapy starts. One cycle is 3 weeks. Patients should have recovered fully from the first cycle of chemotherapy before they continue with the concurrent chemo radiation part.

Patients will be entered in cohorts of three.



The first cohort of patients will receive three-weekly infusions of pemetrexed at a dose of 400 mg/m2 and cisplatin 60 mg/m2 which will be administered on the morning of Day 1 of the second course of chemotherapy. Radiotherapy will be administered 2 hours after the chemotherapy administration, at an initial dose of 66 Gy in 33 fractions over 45 days. Each agent will be escalated independently, to allow further cohorts to be treated while allowing at least 6 weeks after the completion of radiotherapy to assess acute toxicity. At any dose level, before escalation of the dose of that agent, all 3 patients treated in the previous cohort in which that agent was escalated, or in cohort 1, must have completed the entire 6 weeks of treatment and have been assessed for acute toxicity 6 weeks after completing radiotherapy. In case of grade 4 dose-limiting toxicity no further treatment or escalation is allowed. If 1 patient experiences a grade 3 dose-limiting toxicity, a further 3 patients will be treated at that dose level. If no patients in the second trio experience a dose-limiting toxicity, dose escalation may continue. If one additional instance of dose-limiting toxicity occurs (total 2 of 6 patients within one cohort), dose escalation will be stopped and the cohort will be expanded to 9 patients. If no more than 3 of 9 patients experience DLT the MTD is confirmed.

Primary Outcome(s)

The primary objective of this study is to determine the maximum tolerated dose of pemetrexed, cisplatin and radical involved-field radiotherapy in the treatment of patients with unresectable Stage III NSCLC. Two MTD?s will be determined:

1. MTD of pemetrexed and cisplatin in combination with conventional radiotherapy .

2. MTD of pemetrexed and cisplatin with hypofractionated radiotherapy.

Secondary Outcome(s)

The secondary objectives of this study are the following:

1. the incidence and nature of acute toxicities.

2. the incidence and nature of delayed toxicity at 3-6-12 months after final radiotherapy treatment

3. objective tumour response

4. progression free survival

5. overall survival

Secondary ID(s)

ISRCTN91946477

N/A

Source(s) of Monetary Support

Eli Lilly Nederland B.V.